The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...
Oral semaglutide lowered HbA1c vs placebo in a phase 3 trial in adolescents with type 2 diabetes, pending full data and ...
In today's ACT Brief, we explore organizational factors behind CRL decisions, methodological concerns with pooling amyloid ...
In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how ...
A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...
In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, explains why ...
In today's ACT Brief, we explore practical community engagement strategies that drive representative enrollment, how sponsors ...
In today's ACT Brief, we explore practical steps sponsors can take to prepare for the plausible mechanism framework, how ...
In this video interview, Del Smith, PhD, CEO and co-founder of Acclinate, outlines what a practical, sustained community ...
In this Q&A, Mwango Kashoki, MD, MPH, SVP and global head of regulatory strategy at Parexel, breaks down the FDA's plausible ...
In today's ACT Brief, we explore how disease heterogeneity confounds natural history controls, the execution translation gap ...
In today's ACT Brief, we examine how protocol interpretation and source document preparation delay study startup, how the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results